Skip to main content

Table 1 Summary of demographic and clinical parameters of SSc patients

From: Nintedanib downregulates the transition of cultured systemic sclerosis fibrocytes into myofibroblasts and their pro-fibrotic activity

Mean age ± standard deviation (years) 58 ± 11
Sex (F/M) 16/2
Mean Disease duration (years) 9.7 ± 6.9
Anti-Scl70 (n = %) 10 (55.5%)
CENP-A and CENP-B (n = %) 8 (44.5%)
ILD at CTscan (Yes/No) 11 (61.1%) / 7 (38.9%)
Skin involvement (lcSSc / dcSSc) 14 (77.7%) / 4 (22.3%)
NVC patterns (E/A/L) 2 (11.1%) / 10 (55.5%) / 6 (33.4%)
Therapy No immunosuppressor = 7 (38.9%)
MMF = 7 (38.9%)
MTX = 2 (11.1%)
Cyclosporine = 2 (11.1%)
Endothelin receptor antagonists = 8 (44.4%)
  1. Demographic and clinical parameters of enrolled SSc patients. Data include the age, female and male (F/M) ratio, skin involvement, nailfold videocapillaroscopy pattern of microan giopathy and auto-antibody profile. Data are expressed as means ± standard deviations (SD) or numbers (percentages of the total population). lcSSc “limited” cutaneous skin involve ment, dcSSc “diffuse” cutaneous skin involvement, NVC nailfold videocapillaroscopy, E “Early” NVC pattern of microangiopathy, A “Active” NVC pattern of microangiopathy, L “Late” NVC pattern of microangiopathy, CENP anti-centromere antibodies, Scl70 anti-topoisomerase-I antibodies, MMF mycophenolate mofetil, MTX methotrexate